A Phase 3 interventional study of Human Normal Immunoglobulin for Subcutaneous Administration (IGSC) in Common Variable Immunodeficiency, X-linked Agammaglobulinemia and Autosomal Recessive Agammaglobulinemia, sponsored by CSL Behring. Completed at 19 sites in 9 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-09-01.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).
This study consisted of a 12-week wash-in/wash-out period followed by a 28-week efficacy period. During the 28-week efficacy period, subjects visited the study site at least every 4 weeks for efficacy and safety evaluations and additionally recorded details regarding IgPro20 dose and certain aspects of efficacy and safety in a diary. Pharmacokinetic (PK) parameters were assessed in a sub-group of subjects during 1 treatment interval at steady-state (Week 28 ± 1).
54 studies on the registry are indexed under Common Variable Immunodeficiency; 13 are open to participants now.
This study's enrollment of 51 is above the median of 40 across 39 interventional studies indexed under Common Variable Immunodeficiency.
Browse Common Variable Immunodeficiency studies →CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
First submitted after CSL Behring became part of CSL Limited.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional criteria may apply and examination by an investigator is required to determine eligibility.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)
IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
Also known as: Hizentra, SCIG
Total Serum IgG Trough Levels
Total IgG trough levels for IgPro20 treatment at steady state were compared with documented trough level data for IgG treatment received prior to enrolling in the study (either subcutaneous or intravenous IgG). For this purpose, 6 consecutive IgPro20 trough values (obtained prior to infusions 12 to 17) per subject were aggregated to the subject's median value and then median values across subjects were summarised using descriptive statistics. The same procedure was applied to pre-study treatment using the 3 most recent IgG trough values ≥ 5 g/L obtained prior to the first IgPro20 infusion.
Time frame: Up to 6 months prior to first IgPro20 treatment (Pre-study treatment) and Week 12 to 17 (IgPro20 treatment)
Annual Rate of Clinically Documented Serious Bacterial Infections (ITT Population)
Serious bacterial infections (SBIs) included bacterial pneumonia, bacteraemia/septicaemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. Diagnosis of the SBIs was based on the presence of predefined clinical signs and symptoms as well as on laboratory parameters. The annual rate was calculated based on the total number of SBIs and the total number of study days during the efficacy period for all subjects in the ITT population and adjusted to 365 days.
Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit
Annual Rate of Clinically Documented Serious Bacterial Infections (PPE Population)
Serious bacterial infections (SBIs) included bacterial pneumonia, bacteraemia/septicaemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. Diagnosis of the SBIs was based on the presence of predefined clinical signs and symptoms as well as on laboratory parameters. The annual rate was calculated based on the total number of SBIs and the total number of study days during the efficacy period for all subjects in the PPE population and adjusted to 365 days.
Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit
Annual Rate of Infection Episodes
The annual rate of episodes was calculated based on the total number of any infection type and the total number of study days during the efficacy period for all subjects in the ITT population and adjusted to 365 days.
Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit
Annual Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections
The annual rate was calculated based on the total number of days out of work/school/kindergarten/day care or unable to perform normal activities due to infections in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.
Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit
Annual Rate of the Number of Days of Hospitalization Due to Infections
The annual rate was calculated based on the total number of days of hospitalization due to infections in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.
Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit
Annual Rate of Antibiotic Use for Infection Prophylaxis and Treatment
The annual rate was calculated based on the total number of days of antibiotic use in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.
Time frame: Efficacy period: week 12 to week 40 after study start or to the completion visit
Maximum Concentration (Cmax) of Total Serum IgG
Time frame: Week 28 (±1week)
Timepoint of Maximum Concentration (Tmax) of Total Serum IgG
Time frame: Week 28 (±1week)
Area Under the Concentration-Time Curve (AUC_last) of Total Serum IgG
AUC_last = Area under the concentration-time curve until last measured concentration.
Time frame: Week 28 (±1week)
Area Under the Concentration-Time Curve (AUCτ) of Total Serum IgG
AUCτ = Area under the concentration-time curve during regular dosing interval;
Time frame: Week 28 (±1week)
This multinational study enrolled subjects at 15 of the participating study centers in Europe.
| Milestone | IgPro20 (All Treated) |
|---|---|
| Started | 51 |
| Completed | 46 |
| Not completed | 5 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Adverse event | 3 |
| Milestone | IgPro20 (All Treated) |
|---|---|
| Started | 46 |
| Completed | 43 |
| Not completed | 3 |
| Withdrew: Adverse event | 3 |
Total IgG trough levels for IgPro20 treatment at steady state were compared with documented trough level data for IgG treatment received prior to enrolling in the study (either subcutaneous or intravenous IgG). For this purpose, 6 consecutive IgPro20 trough values (obtained prior to infusions 12 to 17) per subject were aggregated to the subject's median value and then median values across subjects were summarised using descriptive statistics. The same procedure was applied to pre-study treatment using the 3 most recent IgG trough values ≥ 5 g/L obtained prior to the first IgPro20 infusion.
| g/L | IgPro20 | Pre-study IgG Treatment |
|---|---|---|
| Total Serum IgG Trough Levels | 8.10 ± 1.44 | 7.49 ± 1.57 |
Serious bacterial infections (SBIs) included bacterial pneumonia, bacteraemia/septicaemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. Diagnosis of the SBIs was based on the presence of predefined clinical signs and symptoms as well as on laboratory parameters. The annual rate was calculated based on the total number of SBIs and the total number of study days during the efficacy period for all subjects in the ITT population and adjusted to 365 days.
| SBIs/subject/year | IgPro20 |
|---|---|
| Annual Rate of Clinically Documented Serious Bacterial Infections (ITT Population) | 0 |
Serious bacterial infections (SBIs) included bacterial pneumonia, bacteraemia/septicaemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. Diagnosis of the SBIs was based on the presence of predefined clinical signs and symptoms as well as on laboratory parameters. The annual rate was calculated based on the total number of SBIs and the total number of study days during the efficacy period for all subjects in the PPE population and adjusted to 365 days.
| SBIs/subject/year | IgPro20 |
|---|---|
| Annual Rate of Clinically Documented Serious Bacterial Infections (PPE Population) | 0 |
The annual rate of episodes was calculated based on the total number of any infection type and the total number of study days during the efficacy period for all subjects in the ITT population and adjusted to 365 days.
| episodes/subject/year | IgPro20 |
|---|---|
| Annual Rate of Infection Episodes | 5.18 (4.31 to 6.17) |
The annual rate was calculated based on the total number of days out of work/school/kindergarten/day care or unable to perform normal activities due to infections in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.
| days/subject/year | IgPro20 |
|---|---|
| Annual Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections | 8.00 |
The annual rate was calculated based on the total number of days of hospitalization due to infections in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.
| days/subject/year | IgPro20 |
|---|---|
| Annual Rate of the Number of Days of Hospitalization Due to Infections | 3.48 |
The annual rate was calculated based on the total number of days of antibiotic use in the efficacy period divided by the total number of days in the efficacy period for all subjects and adjusted to 365 days.
| days/subject/year | IgPro20 |
|---|---|
| Annual Rate of Antibiotic Use for Infection Prophylaxis and Treatment | 72.75 |
| g/L | IgPro20 (PK Substudy) |
|---|---|
| Maximum Concentration (Cmax) of Total Serum IgG | 8.26 ± 1.25 |
| day | IgPro20 (PK Substudy) |
|---|---|
| Timepoint of Maximum Concentration (Tmax) of Total Serum IgG | 2.06 (0.94 to 6.92) |
AUC_last = Area under the concentration-time curve until last measured concentration.
| day x g/L | IgPro20 (PK Substudy) |
|---|---|
| Area Under the Concentration-Time Curve (AUC_last) of Total Serum IgG | 53.70 ± 9.16 |
AUCτ = Area under the concentration-time curve during regular dosing interval;
| day x g/L | IgPro20 (PK Substudy) |
|---|---|
| Area Under the Concentration-Time Curve (AUCτ) of Total Serum IgG | 53.61 ± 9.98 |
Collected over The observation period for adverse events was from the time the subjects had given informed consent until they had the final examination (completion visit up to 40 weeks) or extended when serious adverse events were reported.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IgPro20 (All Treated) | — | 5/51 (9.8%) | 50/51 (98%) |
| Event | IgPro20 (All Treated) |
|---|---|
| DiarrhoeaGastrointestinal disorders | 1/51 |
| PneumoniaInfections and infestations | 1/51 |
| PyrexiaGeneral disorders | 1/51 |
| BronchiolitisInfections and infestations | 1/51 |
| AppendicitisInfections and infestations | 1/51 |
| SciaticaNervous system disorders | 1/51 |
| Event | IgPro20 (All Treated) |
|---|---|
| BronchitisInfections and infestations | 16/51 |
| PyrexiaGeneral disorders | 14/51 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/51 |
| HeadacheNervous system disorders | 13/51 |
| NasopharyngitisInfections and infestations | 12/51 |
| Upper respiratory tract infectionInfections and infestations | 12/51 |
| DiarrhoeaGastrointestinal disorders | 10/51 |
| Injection site reactionGeneral disorders | 9/51 |
| SinusitisInfections and infestations | 7/51 |
| Injection site painGeneral disorders | 6/51 |
| Age Continuous(years) | IgPro20 (All Treated) |
|---|---|
| Mean | 22.6 ± 16.02 |
| Age, Customized(Participants) | IgPro20 (All Treated) |
|---|---|
| 2 to < 12 years | 18 |
| 12 to < 16 years | 5 |
| 16 to < 65 years | 28 |
| Sex: Female, Male(Participants) | IgPro20 (All Treated) |
|---|---|
| Female | 16 |
| Male | 35 |
| Race/Ethnicity, Customized(Participants) | IgPro20 (All Treated) |
|---|---|
| White | 51 |
| Type of Primary Immunodeficiency(Participants) | IgPro20 (All Treated) |
|---|---|
| Common variable immunodeficiency (CVID) | 30 |
| X-linked agammaglobulinemia (XLA) | 20 |
| Autosomal recessive agammaglobulinemia (ARAG) | 1 |
The record gives a start of Sep 2007, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hizentra
Common Variable Immunodeficiency →